Innovative Targeted and Immune-Mediated Cancer Therapies


Developing first-in-class small molecule product candidates with broad potential benefit to patients

Learn more


Modulating validated and new pathways to develop novel therapeutics

Learn more


March 29, 2021
Tempest and Millendo Announce Proposed Merger Agreement 

March 8, 2021
Tempest Therapeutics to Present at the Solebury Trout/Credit Suisse/Cooley Private Company Showcase

March 3, 2021
Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma 

More news


Tempest and Millendo Proposed Merger Investor Call
Monday, March 29, 2021 at 8:30 am Eastern Time
Presentation: Proposed Merger of Tempest and Millendo pdf

Solebury Trout/Credit Suisse/Cooley Private Company Showcase
Thursday, March 11, 2021 at 3:40 pm Eastern Time